NCT04575181View on ClinicalTrials.gov

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

December 24, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0268-0965

For subcutaneous (s.c., under the skin) injection once daily for 26 weeks

DRUG

Insulin glargine

For s.c. injection once daily for 26 weeks

DRUG

Placebo (NNC0268-0965)

For s.c. injection once daily for 26 weeks

DRUG

Placebo (insulin glargine)

For s.c. injection once daily for 26 weeks

Trial Locations (2)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

55116

Profil GmbH & Co. KG, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY